Suivre
Massimo Riccaboni
Titre
Citée par
Citée par
Année
The productivity crisis in pharmaceutical R&D
F Pammolli, L Magazzini, M Riccaboni
Nature reviews Drug discovery 10 (6), 428-438, 2011
11852011
A comparison of US and European university-industry relations in the life sciences
J Owen-Smith, M Riccaboni, F Pammolli, WW Powell
Management science 48 (1), 24-43, 2002
7952002
Technological change and network dynamics: lessons from the pharmaceutical industry
L Orsenigo, F Pammolli, M Riccaboni
Research policy 30 (3), 485-508, 2001
6002001
Innovation and corporate growth in the evolution the pharmaceutical industry
G Bottazzi, G Dosi, F Pammolli, M Riccaboni
International Journal of Industrial Organization 19 (7), 1161-1187, 2000
542*2000
Does co-location matter for formal knowledge collaboration in the Swedish biotechnology–pharmaceutical sector?
M McKelvey, H Alm, M Riccaboni
Research policy 32 (3), 483-501, 2003
3932003
Reputation and impact in academic careers
AM Petersen, S Fortunato, RK Pan, K Kaski, O Penner, A Rungi, ...
Proceedings of the National Academy of Sciences 111 (43), 15316-15321, 2014
3102014
The growth of business firms: Theoretical framework and empirical evidence
D Fu, F Pammolli, SV Buldyrev, M Riccaboni, K Matia, K Yamasaki, ...
Proceedings of the National Academy of Sciences 102 (52), 18801-18806, 2005
2522005
World input-output network
F Cerina, Z Zhu, A Chessa, M Riccaboni
PloS one 10 (7), e0134025, 2015
2302015
Persistence and uncertainty in the academic career
AM Petersen, M Riccaboni, HE Stanley, F Pammolli
Proceedings of the National Academy of Sciences 109 (14), 5213-5218, 2012
1982012
The sustainability of European health care systems: beyond income and aging
F Pammolli, M Riccaboni, L Magazzini
The European Journal of Health Economics 13, 623-634, 2012
1512012
The evolution of networks of innovators within and across borders: Evidence from patent data
A Morescalchi, F Pammolli, O Penner, AM Petersen, M Riccaboni
Research Policy 44 (3), 651-668, 2015
1302015
Innovation and competitiveness in European biotechnology
F Pammolli, A Allansdottir, A Bonaccorsi, A Gambardella, M Mariani, ...
Office for Official Publications of the European Communities, 2002
1232002
Dynamic competition in pharmaceuticals: patent expiry, generic penetration, and industry structure
L Magazzini, F Pammolli, M Riccaboni
The European Journal of Health Economics, formerly: HEPAC 5, 175-182, 2004
1222004
A multi-level geographical study of Italian political elections from Twitter data
G Caldarelli, A Chessa, F Pammolli, G Pompa, M Puliga, M Riccaboni, ...
PloS one 9 (5), e95809, 2014
1202014
Is Europe evolving toward an integrated research area?
A Chessa, A Morescalchi, F Pammolli, O Penner, AM Petersen, ...
Science 339 (6120), 650-651, 2013
1202013
Medical devices competitiveness and impact on public health expenditure
F Pammolli, M Riccaboni, C Oglialoro, L Magazzini, G Baio, N Salerno
1202005
On the size distribution of business firms
J Growiec, F Pammolli, M Riccaboni, HE Stanley
Economics Letters 98, 207-212, 2008
1182008
The impact of the COVID-19 pandemic on scientific research in the life sciences
M Riccaboni, L Verginer
PLoS One 17 (2), e0263001, 2022
1172022
On firm growth in networks
M Riccaboni, F Pammolli
Research Policy 31 (8-9), 1405-1416, 2002
1132002
Evolution of controllability in interbank networks
D Delpini, S Battiston, M Riccaboni, G Gabbi, F Pammolli, G Caldarelli
Scientific reports 3 (1), 1626, 2013
1112013
Le système ne peut pas réaliser cette opération maintenant. Veuillez réessayer plus tard.
Articles 1–20